Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
7.46
-0.56 (-6.98%)
Mar 31, 2025, 1:23 PM EDT - Market open
Cullinan Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Cullinan Therapeutics stock have an average target of 32.86, with a low estimate of 26 and a high estimate of 40. The average target predicts an increase of 340.48% from the current stock price of 7.46.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cullinan Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Initiates $38 → $35 | Buy | Initiates | $38 → $35 | +369.17% | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $33 | Strong Buy | Reiterates | $33 | +342.36% | Feb 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $28 → $33 | Strong Buy | Maintains | $28 → $33 | +342.36% | Jan 29, 2025 |
| UBS | UBS | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +302.14% | Oct 24, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +275.34% | Oct 16, 2024 |
Financial Forecast
Revenue This Year
8.56M
Revenue Next Year
32.37M
from 8.56M
Increased by 278.37%
EPS This Year
-3.41
from -3.11
EPS Next Year
-3.17
from -3.41
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 47.3M | 84.0M | 251.8M | ||
| Avg | 8.6M | 32.4M | 45.6M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 881.8% | 677.8% | ||
| Avg | - | 278.4% | 40.9% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.02 | -2.39 | -2.00 | ||
| Avg | -3.41 | -3.17 | -3.36 | ||
| Low | -3.66 | -3.97 | -4.51 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.